When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial.

Costanza De Rossi, Antonella Brunello, Giuseppe Jirillo, Antonio Jirillo

Research output: Contribution to journalArticlepeer-review

Abstract

About 30% of the randomized clinical trials are stopped early because of appearance of clear clinical benefit. Though interim analyses protect patients in case of significant imbalance between two treatment arms, conclusions drawn from truncated studies can be premature and should be viewed with caution. We report the lesson learnt from the Herceptin adjuvant (HERA) trial.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalImmunopharmacology and Immunotoxicology
Volume31
Issue number1
DOIs
Publication statusPublished - 2009

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology

Fingerprint Dive into the research topics of 'When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial.'. Together they form a unique fingerprint.

Cite this